Oak Hill Bio raises $32.5M (United States, Jun 2026)
$32.5M
$32.5MGenerated social card
Headline
$32.5M to advance rugonersen into late-stage testing for Angelman - Angelman Syndrome News
About
Oak Hill Bio is a therapeutics company focused on developing treatments for rare diseases. They have secured funding to advance rugonersen, an experimental treatment for Angelman syndrome, into late-stage clinical testing, highlighting their commitment to addressing unmet medical needs in this community.
Article summary
$32.5M to advance rugonersen into late-stage testing for Angelman Angelman Syndrome News
Founder
Josh Distler
CEO
Investors
Related rounds
| Jul 21, 2026 | 30 Sundays | $6.7M | — | United States |
| Jul 21, 2026 | Skylark Labs | $150.0M | — | United States |
| Jul 21, 2026 | Infinity | $15.0M | — | United States |
| Jul 20, 2026 | Natural | $30.0M | Series A | United States |